CXCL10 and type 1 diabetes mellitus: Indeed, in both new-onset diabetic RIP-LCMV as well as NOD mice an administration of three daily doses of a non-Fc-binding anti-CD3ε F(ab’)2 fragment [clone 145-2C11] (63) followed by a treatment with a neutralizing anti-CXCL10 antibody [clone 1F11] (79) resulted in profound remission of T1D (56).